MedTrace Logo

Cetuximab/FOLFIRI With or Without Oxaliplatin and FOLFOXIRI With or Without Bevacizumab in Neoadjuvant Treatment of Non-resectable Colorectal Liver Metastases

NCT01802645 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 91

Last updated 2019-09-11

No results posted yet for this study

Summary

The aim of this study is to investigate the following schedules for efficacy with regard to response rate in neoadjuvant treatment of patients with non-resectable liver metastases:

* Cetuximab/FOLFOXIRI and cetuximab/FOLFIRI in patients with ras wild type tumours and
* Bevacizumab/FOLFOXIRI and FOLFOXIRI in patients with ras mutant tumours.

Conditions

Interventions

DRUG

Cetuximab

DRUG

Bevacizumab

DRUG

Irinotecan

DRUG

Oxaliplatin

DRUG

5-FU

DRUG

Folinic Acid

Sponsors & Collaborators

  • Technische Universität Dresden

    lead OTHER

Principal Investigators

  • Gunnar Folprecht, PD Dr. · University hospital "Carl Gustav Carus" Dresden

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-03-31
Primary Completion
2019-09-30
Completion
2020-12-31

Countries

  • Germany

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01802645 on ClinicalTrials.gov